Merck & Co., Inc. (MRK) Position Decreased by Standard Life Aberdeen plc

Standard Life Aberdeen plc trimmed its stake in Merck & Co., Inc. (NYSE:MRK) by 3.9% during the fourth quarter, HoldingsChannel reports. The fund owned 3,173,231 shares of the company’s stock after selling 129,648 shares during the quarter. Standard Life Aberdeen plc’s holdings in Merck & Co., Inc. were worth $239,198,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the stock. Oregon Public Employees Retirement Fund increased its position in Merck & Co., Inc. by 17,936.7% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 53,150,490 shares of the company’s stock worth $696,000 after buying an additional 52,855,811 shares during the period. Capital International Investors increased its position in Merck & Co., Inc. by 178.2% in the 3rd quarter. Capital International Investors now owns 32,984,606 shares of the company’s stock worth $2,339,928,000 after buying an additional 21,127,887 shares during the period. Jennison Associates LLC increased its position in Merck & Co., Inc. by 323.1% in the 4th quarter. Jennison Associates LLC now owns 15,777,286 shares of the company’s stock worth $1,205,542,000 after buying an additional 12,048,406 shares during the period. BlackRock Inc. increased its position in Merck & Co., Inc. by 5.6% in the 4th quarter. BlackRock Inc. now owns 194,589,541 shares of the company’s stock worth $14,868,587,000 after buying an additional 10,315,510 shares during the period. Finally, Matthew Goff Investment Advisor LLC increased its position in Merck & Co., Inc. by 5,970.0% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 5,369,519 shares of the company’s stock worth $88,460,000 after buying an additional 5,281,059 shares during the period. 73.60% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE:MRK opened at $78.33 on Friday. Merck & Co., Inc. has a 1-year low of $57.49 and a 1-year high of $83.85. The company has a market cap of $210.42 billion, a PE ratio of 18.05, a PEG ratio of 1.89 and a beta of 0.58. The company has a current ratio of 1.17, a quick ratio of 0.92 and a debt-to-equity ratio of 0.74.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $1.22 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.17. Merck & Co., Inc. had a return on equity of 38.85% and a net margin of 19.50%. The company had revenue of $10.82 billion for the quarter, compared to analyst estimates of $10.45 billion. During the same quarter last year, the firm earned $1.05 EPS. Merck & Co., Inc.’s revenue for the quarter was up 7.8% compared to the same quarter last year. Research analysts expect that Merck & Co., Inc. will post 4.72 EPS for the current year.

Several brokerages have commented on MRK. ValuEngine raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. UBS Group lifted their price target on Merck & Co., Inc. from $87.00 to $88.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Bank of America lifted their price target on Merck & Co., Inc. from $90.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. BMO Capital Markets lifted their price target on Merck & Co., Inc. from $83.00 to $84.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 1st. Finally, Zacks Investment Research raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $93.00 price target on the stock in a research report on Monday, April 1st. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Merck & Co., Inc. has an average rating of “Buy” and an average price target of $82.92.

In related news, Director Wendell P. Weeks sold 5,000 shares of the business’s stock in a transaction on Wednesday, February 13th. The stock was sold at an average price of $78.71, for a total value of $393,550.00. Following the sale, the director now owns 5,100 shares of the company’s stock, valued at approximately $401,421. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Chairman Kenneth C. Frazier sold 18,725 shares of the business’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $82.00, for a total value of $1,535,450.00. Following the completion of the sale, the chairman now directly owns 816,440 shares in the company, valued at approximately $66,948,080. The disclosure for this sale can be found here. Insiders have sold a total of 910,014 shares of company stock worth $73,507,953 in the last three months. 0.27% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This story was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/05/10/merck-co-inc-mrk-position-decreased-by-standard-life-aberdeen-plc.html.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

See Also: Earnings Per Share (EPS)

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.